Amyloid-Journal of Protein Folding Disorders

Papers
(The H4-Index of Amyloid-Journal of Protein Folding Disorders is 17. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-11-01 to 2025-11-01.)
ArticleCitations
Impact of autonomic dysfunction in light chain amyloidosis patient with nephrotic syndrome and cardiac involvement270
Changes in the amyloid editorial board members and in editor positions262
A case of asymmetric insulin-derived localised amyloid deposition associated with long-acting insulin analog administration106
A second case of liraglutide-type localised amyloidosis93
Neurofilament light chain as a biomarker for hereditary ATTR amyloidosis − correlation between neurofilament light chain and nerve conduction study73
Re-evaluation of Mayo 2004 and revised Mayo 2012 staging in patients with AL amyloidosis in the era of new therapies73
Comparison between tafamidis and liver transplantation as first-line therapy for hereditary transthyretin amyloidosis49
Factors associated with financial toxicity in patients with transthyretin amyloidosis: results from Amyloidosis Research Consortium’s treatment affordability patient and caregiver survey34
Real-world treatment patterns, costs, and outcomes in patients with AL amyloidosis: analysis of the Optum EHR and commercial claims databases30
Role of complementarity-determining regions 1 and 3 in pathologic amyloid formation by human immunoglobulin κ1 light chains25
Reduction of cardiac AL amyloid deposition after complete response visualised by PiB-PET imaging23
A novel transthyretin variant p.Val114Glu (Val94Glu) in an Italian patient with mixed phenotype hereditary transthyretin amyloidosis22
Characterising diflunisal as a transthyretin kinetic stabilizer at relevant concentrations in human plasma using subunit exchange21
Early cardiovascular autonomic failure in ATTRv predicts poor prognosis and may respond to disease-modifying therapy21
Abnormal global longitudinal strain and reduced serum inflammatory markers in cardiac AL amyloidosis patients without significant amyloid fibril deposition20
Clinical impact of beta-blocker withdrawal in transthyretin amyloid cardiomyopathy18
Genetic landscape of hereditary transthyretin amyloidosis in Spain: a multicentric retrospective study18
Human lysozyme inhibits the fibrillation of serum amyloid a protein from systemic AA amyloidosis17
0.79166316986084